Abstract: Oral compositions, such as toothpastes, mouthwashes, lozenges and chewing gum, containing a chlorous acid liberating material, and an antidemineralization agent such as indium are disclosed.

Abstract: Trienamide and tetraenamide compounds, and pharmaceutically-acceptable salts thereof, of the formula: ##STR1## wherein R is a straight or branched chain tri-unsaturated or tetra-unsaturated fatty acid amide having from 14 to 24 carbon atoms, exhibit anit-inflammatory and analgesic activity when administered to humans or lower animals.

Abstract: Novel antitussive and anesthesic liquid compositions of matter for oral use comprising an effective oral antitussive drug and phenol, and method of using same.

Abstract: Disclosed are medicated cleansing pads comprising:(a) from about 50% to about 75% of two or more layers of nonwoven fabric materials;(b) from about 20% to about 75% (on a dry solids basis) of a water soluble polymeric resin of the formula: ##STR1## wherein A is one or more monomers selected from styrene or styrene derivatives and B is one or more monomers selected from butadiene or butadiene derivatives, x is the number of different A monomer components present in the copolymer chain, with x being an integer of 1 or more and y is the number of B monomer components present in the copolymer chain, with y being an integer of 0 or more and m:n is the weight ratio of A monomer components to B monomer components, and is from about 10:1 to about 1:5; and(c) from about 0.1% to about 50.0% of a salicylic acid active composition.This invention also encompasses a method of treating acne in humans and lower animals comprising topically applying to the affected area the medicated pads of the present invention.

Abstract: Disclosed are medicated cleansing pads comprising: (a) from about 50% to about 75% of a nonwoven fabric material; (b) from about 20% to about 75% (on a dry solids basis) of a water soluble polymeric resin of the formula:(A.sub.x).sbsb.m (B.sub.y).sbsb.nwherein A is one or more monomers selected from styrene or styrene derivatives and B is one or more monomers selected from butadiene or butadiene derivatives, x is the number of different A monomer components present in the copolymer chain, with x being an integer of 1 or more and y is the number of B monomer components present in the copolymer chain, with y being an integer of 0 or more and m:n is the weight ratio of A monomer components to B monomer components, and is from about 10:1 to about 1:5, preferably from about 5:1 to about 1:2, and (c) from about 0.1% to about 50% of salicylic acid active composition.

Abstract: The present invention relates to methods for treating or preventing dental plaque, caries, or gingival or periodontal diseases of the oral cavity in humans or lower animals, with reduced staining of teeth or dentures. The methods comprise topically applying to the oral surfaces of the teeth or dentures of the humans or lower animals:(a) a safe and effective amount of a monoperoxyphthalate compound, and(b) a safe and effective amount of an anti-plaque bis-biguanide compound.The present invention also relates to compositions for achieving such treatments.

Abstract: The invention relates to androstane-17-carboxylic acid esters, represented by general formula (I): ##STR1## wherein R.sub.1 represents a lower alkyl group containing 1 to 4 carbon atoms, a lower alkyl group containing 2 to 4 carbon atoms substituted by an amino group, or an aralkyl group from 6 to 12 carbon atoms, R.sub.2 and R.sub.3, which may be the same or different, represent a hydrogen atom or a lower alkyl group containing 1 to 4 carbon atoms, R.sub.4 represents a hydrogen atom, a hydroxy group or an acetoxy group, R.sub.5 represents a hydroxy or acetoxy group, or R.sub.4 and R.sub.5 represent together a divalent alkylenedioxy group, R.sub.6 represents a hydroxy group, a methoxy group, or an acetoxy group, R.sub.7 represents a methyl group or a hydroxymethyl group, R.sub.8 represents an hydrogen atom or a hydroxy group and ##STR2## represents either a ##STR3## group or a ##STR4## carbon atom having the double linkage in the 4- or 5-position of the steroid nucleus.

Abstract: The present invention involves certain N-hydroxy-5-phenyl-2-furancarboximidamides, pharmaceutical compositions containing such compounds, and methods for increasing the contractile force of cardiac muscle of a mammal which comprises systemically administering such compounds to a mammal.

Abstract: The invention involves a method for treating or preventing a malignant hyperthermic reaction in a human or lower animal by administering a safe and effective amount of azumolene.

Abstract: Pantethine and pantetheine in permanent waving operations for hair to increase waving efficiency.

Abstract: The present invention involves compounds having the structure: ##STR1## (a) --A-- is selected from the group consisting of ##STR2## (b) --Y is selected from certain low molecular weight moieties which terminate in specific functional groups: --C.tbd.CH, ##STR3## and aldehydes in the form of their acetals; pharmaceutical compositions comprising such compounds; and methods for treating inflammation by administering such compounds.

Abstract: Dentifrice compositions are disclosed which have an improved pearlescence.

Abstract: The present invention involves compounds having the structure: ##STR1## wherein: (a) --A.sup.1 is selected from the group consisting of --OH, --H, and --O.sub.2 CR;(b) --A.sup.2 is selected from the group consisting of unsubstituted or substituted, saturated or unsaturated, straight, branched and cyclic alkyl having from 1 to about 10 carbon atoms;(c)--A.sup.3 is selected from --C(CH.sub.3).sub.3, --Si(CH.sub.3).sub.3, and --CF.sub.3 ; and(d) --Y is selected from certain low molecular weight alkyl chains which terminate in specific unsaturated functional groups: ##STR2## and aldehydes in the form of their acetals; pharmaceutical compositions comprising such compounds; and methods for treating inflammation by administering such compounds.

Abstract: The present invention relates to oral compositions, such as dentrifices, toothpastes and mounthwashes, which provide an anticalculus benefit. These compositions comprise a safe and effective amount of an anticalculus agent which is a polyepoxysuccinic acid, or its pharmaceutically-acceptable salts, along with a pharmaceutically-acceptable carrier. The present invention also relates to a method for inhibiting or reducing the development of dental calculus by contacting the oral cavity with a safe and effective amount of an anticalculus agent which is a polyepoxysuccinic acid, or its pharmaceutically-acceptable salt.

Abstract: Disclosed are oral compositions which are effective against calculus and contain a chelating agent which is an acrylic acid polymer or copolymer or EDTA, a strontium ion source, a fluoride ion source and a pyrophosphate ion source.

Abstract: This invention relates to a new composition for washing and conditioning hair, and more particularly a new composition providing both a shampooing and a conditioning action in a single application.

Abstract: Diphosphonate-derivatized macromolecules, such as proteins, suitable for use as technetium-99m-based scanning agents and as anticalcification agents are disclosed. The scanning agents are prepared by combining Tc-99m in a +3, +4 and/or +5 oxidation state with the diphosphonate-derivatized macromolecules. Also disclosed are pharmaceutical compositions containing these diphosphonate-derivatized macromolecules and methods for scintigraphic imaging using these diphosphonate-derivatized macromolecules labeled with Tc-99m.

Abstract: The invention involves a method for achieving systemic administration of azumolene by delivering the drug to the intestines without exposing the drug in the stomach, and pharmaceutical compositions for achieving such administration of azumolene.

Abstract: Methods which reduce natural stain from teeth are described.

Abstract: A method for treating or preventing osteoporosis is disclosed. Bone cells are synchronized during a bone cell activating period; bone resorption, which normally follows activation, is inhibited using a polyphosphonate; bone formation is allowed to occur in the rest period during which nutrient supplements may be administered to the patient. The method shortens the natural cycle time of bone formation/resorption, resulting in a faster bone build-up.